Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC By Ogkologos - March 17, 2025 440 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR People with Cancer Say Access to Their Clinical Notes Is Valuable November 18, 2020 Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line... June 7, 2023 EMA Recommends Granting a Marketing Authorisation for Lazertinib December 4, 2024 Large Study Confirms that HPV Vaccine Prevents Cervical Cancer October 14, 2020 Load more HOT NEWS Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in... Celebrating 10 years of partnership with NIVEA Sun ESMO Gynaecological Cancers Congress 2023
